Back to search
ALK-Positive Large B-Cell Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which ALK-Positive Large B-Cell Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which ALK-Positive Large B-Cell Lymphoma trials you may qualify forThis study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to…
This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of pati…
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or rec…
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients…
This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating pat…
In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell ly…